Clinical Trial Update: Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating multiple ascending doses of Rozibusp Alfa (AMG 570) in adults with rheumatoid arthritis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rozibafusp Alfa (AMG 570) (rozibafusp alfa)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2023-04-03